GlassScriptPhysician profile
Jamie B Mitnick
NPI 1437343084
$4,201.43
in general payments reported to CMS, 2019-2025
23 companies · $946 in 2025
The $946 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $841 · 2023: $672 · 2024: $1,610 · 2025: $946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $776.99 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $428.33 | 2022-2025 | |
| Abbvie INC. | $399.19 | 2022-2025 | |
| Lilly USA, LLC | $348.13 | 2022-2024 | Jardiance, Zepbound |
| Optinose US, INC. | $254.62 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $239.06 | 2023-2024 | Quviviq |
| Edwards Lifesciences Corporation | $200.37 | 2023-2024 | |
| Pfizer INC. | $190.11 | 2023-2025 | |
| Biomerieux INC | $173.01 | 2025 | |
| Glaxosmithkline, LLC. | $171.77 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boston Scientific Corporation | $137.15 | 2023 | Watchman Flx |
| Neurocrine Biosciences, INC. | $132.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $118.45 | 2024 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $116.18 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $113.51 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $111.95 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $71.90 | 2025 | |
| Organon LLC | $67.88 | 2025 | Vtama |
| Amgen INC. | $46.02 | 2022-2025 | Evenity, Prolia, Repatha |
| Amarin Pharma, INC. | $37.59 | 2022 | |
| Incyte Corporation | $34.89 | 2025 | Opzelura |
| Janssen Pharmaceuticals, INC | $17.75 | 2022 | |
| Currax Pharmaceuticals LLC | $14.50 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Mitnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.